IL140499A - Nalladase inhibitors useful as pharmaceutical compounds and compositions - Google Patents

Nalladase inhibitors useful as pharmaceutical compounds and compositions

Info

Publication number: IL140499A
Authority: IL; Israel
Prior art keywords: formula; compound; moiety; acid; pentanedioic acid
Prior art date: 1998-07-06

Application number

IL140499A

Other languages

English (en)

Original Assignee

Eisai Corp North America

Mgi Gp Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-06

Filing date

2000-12-22

Publication date

2006-12-31

1998-07-06 Priority claimed from US09/110,262 external-priority patent/US6395718B1/en

1999-01-12 Priority claimed from US09/228,391 external-priority patent/US6265609B1/en

1999-07-02 Priority claimed from PCT/US1999/015128 external-priority patent/WO2000001668A2/fr

2000-12-22 Application filed by Eisai Corp North America, Mgi Gp Inc filed Critical Eisai Corp North America

2006-12-31 Publication of IL140499A publication Critical patent/IL140499A/en

Links

150000001875 compounds Chemical class 0.000 title claims description 196
239000003112 inhibitor Substances 0.000 title claims description 86
239000000203 mixture Substances 0.000 title claims description 48
-1 hydroxy, carboxy, carbonyl Chemical group 0.000 claims description 114
238000000034 method Methods 0.000 claims description 83
238000011282 treatment Methods 0.000 claims description 72
206010028980 Neoplasm Diseases 0.000 claims description 66
230000000694 effects Effects 0.000 claims description 65
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 60
229930195712 glutamate Natural products 0.000 claims description 60
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 59
208000006011 Stroke Diseases 0.000 claims description 52
206010012601 diabetes mellitus Diseases 0.000 claims description 52
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
239000002253 acid Substances 0.000 claims description 44
239000003814 drug Substances 0.000 claims description 42
125000003342 alkenyl group Chemical group 0.000 claims description 41
125000000217 alkyl group Chemical group 0.000 claims description 41
125000000392 cycloalkenyl group Chemical group 0.000 claims description 39
241000124008 Mammalia Species 0.000 claims description 38
201000011510 cancer Diseases 0.000 claims description 38
208000035475 disorder Diseases 0.000 claims description 35
229910052739 hydrogen Inorganic materials 0.000 claims description 35
239000001257 hydrogen Substances 0.000 claims description 35
208000002193 Pain Diseases 0.000 claims description 33
230000033115 angiogenesis Effects 0.000 claims description 29
201000010099 disease Diseases 0.000 claims description 29
125000001424 substituent group Chemical group 0.000 claims description 28
229910052717 sulfur Inorganic materials 0.000 claims description 26
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 24
230000036407 pain Effects 0.000 claims description 24
239000011593 sulfur Substances 0.000 claims description 24
125000000753 cycloalkyl group Chemical group 0.000 claims description 23
208000028867 ischemia Diseases 0.000 claims description 22
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 21
230000001537 neural effect Effects 0.000 claims description 21
230000005856 abnormality Effects 0.000 claims description 19
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 17
230000002401 inhibitory effect Effects 0.000 claims description 17
238000002360 preparation method Methods 0.000 claims description 17
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 16
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
150000002431 hydrogen Chemical class 0.000 claims description 16
206010013663 drug dependence Diseases 0.000 claims description 15
206010060862 Prostate cancer Diseases 0.000 claims description 14
125000003368 amide group Chemical group 0.000 claims description 14
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
230000006378 damage Effects 0.000 claims description 14
125000001188 haloalkyl group Chemical group 0.000 claims description 14
201000000980 schizophrenia Diseases 0.000 claims description 14
125000003396 thiol group Chemical group [H]S* 0.000 claims description 14
FNLNSQHJKVQCBP-UHFFFAOYSA-N 2-(3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCCS FNLNSQHJKVQCBP-UHFFFAOYSA-N 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
208000017497 prostate disease Diseases 0.000 claims description 13
208000011117 substance-related disease Diseases 0.000 claims description 13
208000018737 Parkinson disease Diseases 0.000 claims description 12
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
125000002837 carbocyclic group Chemical group 0.000 claims description 12
125000000623 heterocyclic group Chemical group 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 11
208000012902 Nervous system disease Diseases 0.000 claims description 10
125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims description 10
GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims description 10
230000004770 neurodegeneration Effects 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
125000005031 thiocyano group Chemical group S(C#N)* 0.000 claims description 10
208000014674 injury Diseases 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
208000016192 Demyelinating disease Diseases 0.000 claims description 8
210000002569 neuron Anatomy 0.000 claims description 8
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 8
208000027418 Wounds and injury Diseases 0.000 claims description 7
150000002500 ions Chemical class 0.000 claims description 7
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
XZOBZHOOPYYQLF-UHFFFAOYSA-N 2-(2-sulfanylpropyl)pentanedioic acid Chemical compound CC(S)CC(C(O)=O)CCC(O)=O XZOBZHOOPYYQLF-UHFFFAOYSA-N 0.000 claims description 6
208000007848 Alcoholism Diseases 0.000 claims description 6
208000029028 brain injury Diseases 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
208000033808 peripheral neuropathy Diseases 0.000 claims description 6
230000000638 stimulation Effects 0.000 claims description 6
208000000094 Chronic Pain Diseases 0.000 claims description 5
201000007930 alcohol dependence Diseases 0.000 claims description 5
210000000278 spinal cord Anatomy 0.000 claims description 5
SMGZBRVSYVJHCB-UHFFFAOYSA-N 2-(2-sulfanylethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCS SMGZBRVSYVJHCB-UHFFFAOYSA-N 0.000 claims description 4
OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 claims description 4
208000030814 Eating disease Diseases 0.000 claims description 4
208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
235000014632 disordered eating Nutrition 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
239000000376 reactant Substances 0.000 claims description 4
208000022497 Cocaine-Related disease Diseases 0.000 claims description 3
206010057852 Nicotine dependence Diseases 0.000 claims description 3
208000025569 Tobacco Use disease Diseases 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
230000006931 brain damage Effects 0.000 claims description 3
201000006145 cocaine dependence Diseases 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
208000004296 neuralgia Diseases 0.000 claims description 3
208000021722 neuropathic pain Diseases 0.000 claims description 3
150000003151 propanoic acid esters Chemical class 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
ODRDBLPMDUBXIN-UHFFFAOYSA-N 2-(1-sulfanylpropan-2-yl)pentanedioic acid Chemical compound SCC(C)C(C(O)=O)CCC(O)=O ODRDBLPMDUBXIN-UHFFFAOYSA-N 0.000 claims description 2
YVGAHISZPITMEJ-UHFFFAOYSA-N 2-(2-methyl-3-sulfanylpropyl)pentanedioic acid Chemical compound SCC(C)CC(C(O)=O)CCC(O)=O YVGAHISZPITMEJ-UHFFFAOYSA-N 0.000 claims description 2
YXHYMTRLDHMUDB-UHFFFAOYSA-N 2-(2-sulfanylbutyl)pentanedioic acid Chemical compound CCC(S)CC(C(O)=O)CCC(O)=O YXHYMTRLDHMUDB-UHFFFAOYSA-N 0.000 claims description 2
VJZDXYDMWPFMRN-UHFFFAOYSA-N 2-(3-sulfanylbutyl)pentanedioic acid Chemical compound CC(S)CCC(C(O)=O)CCC(O)=O VJZDXYDMWPFMRN-UHFFFAOYSA-N 0.000 claims description 2
AUDGDJFDXMDNCI-UHFFFAOYSA-N 2-(3-sulfanylpentyl)pentanedioic acid Chemical compound CCC(S)CCC(C(O)=O)CCC(O)=O AUDGDJFDXMDNCI-UHFFFAOYSA-N 0.000 claims description 2
PQLHQOMXYWQCET-UHFFFAOYSA-N 2-(4-methyl-3-sulfanylpentyl)pentanedioic acid Chemical compound CC(C)C(S)CCC(C(O)=O)CCC(O)=O PQLHQOMXYWQCET-UHFFFAOYSA-N 0.000 claims description 2
IYANJJPQEMIVEW-UHFFFAOYSA-N 2-[2-(sulfanylmethyl)butyl]pentanedioic acid Chemical compound CCC(CS)CC(C(O)=O)CCC(O)=O IYANJJPQEMIVEW-UHFFFAOYSA-N 0.000 claims description 2
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 2
231100000874 brain damage Toxicity 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
230000009689 neuronal regeneration Effects 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 9
101000869592 Daucus carota Major allergen Dau c 1 Proteins 0.000 claims 2
102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 2
108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 2
101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Proteins 0.000 claims 2
102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 claims 2
CCYMZXAGFYPCLX-UHFFFAOYSA-N 2-(2-phenyl-2-sulfanylethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(S)C1=CC=CC=C1 CCYMZXAGFYPCLX-UHFFFAOYSA-N 0.000 claims 1
UIIGSGCAFJVHAI-UHFFFAOYSA-N 2-(2-sulfanylhexyl)pentanedioic acid Chemical compound CCCCC(S)CC(C(O)=O)CCC(O)=O UIIGSGCAFJVHAI-UHFFFAOYSA-N 0.000 claims 1
SOOQDICRKKXBHF-UHFFFAOYSA-N 2-[2-(sulfanylmethyl)pentyl]pentanedioic acid Chemical compound CCCC(CS)CC(C(O)=O)CCC(O)=O SOOQDICRKKXBHF-UHFFFAOYSA-N 0.000 claims 1
101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 claims 1
229910006069 SO3H Inorganic materials 0.000 claims 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
230000000926 neurological effect Effects 0.000 claims 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
241000700159 Rattus Species 0.000 description 84
229940126214 compound 3 Drugs 0.000 description 73
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
210000004027 cell Anatomy 0.000 description 49
239000003981 vehicle Substances 0.000 description 49
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
241001465754 Metazoa Species 0.000 description 30
YPOHEPOKCFGNMF-UHFFFAOYSA-N 2-(3-tritylsulfanylpropyl)pentanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCCCC(CCC(=O)O)C(O)=O)C1=CC=CC=C1 YPOHEPOKCFGNMF-UHFFFAOYSA-N 0.000 description 28
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 28
238000002347 injection Methods 0.000 description 28
239000007924 injection Substances 0.000 description 28
239000000243 solution Substances 0.000 description 28
230000002829 reductive effect Effects 0.000 description 27
210000001519 tissue Anatomy 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
229940125904 compound 1 Drugs 0.000 description 23
229940125782 compound 2 Drugs 0.000 description 22
230000005764 inhibitory process Effects 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
210000004556 brain Anatomy 0.000 description 21
241000699670 Mus sp. Species 0.000 description 20
102000004190 Enzymes Human genes 0.000 description 19
108090000790 Enzymes Proteins 0.000 description 19
229940088598 enzyme Drugs 0.000 description 19
OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
229940079593 drug Drugs 0.000 description 18
235000019439 ethyl acetate Nutrition 0.000 description 18
238000001727 in vivo Methods 0.000 description 18
239000003921 oil Substances 0.000 description 18
235000019198 oils Nutrition 0.000 description 18
238000005462 in vivo assay Methods 0.000 description 17
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 17
206010029216 Nervousness Diseases 0.000 description 16
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 16
229960001052 streptozocin Drugs 0.000 description 16
LZICFINGWPMWMI-UHFFFAOYSA-N methyl 3-[2,2-dimethyl-4,6-dioxo-5-(3-tritylsulfanylpropyl)-1,3-dioxan-5-yl]propanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)SCCCC1(CCC(=O)OC)C(=O)OC(C)(C)OC1=O LZICFINGWPMWMI-UHFFFAOYSA-N 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 15
238000001356 surgical procedure Methods 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
229960003920 cocaine Drugs 0.000 description 14
230000012010 growth Effects 0.000 description 14
238000001802 infusion Methods 0.000 description 14
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 13
230000005670 electromagnetic radiation Effects 0.000 description 13
238000001000 micrograph Methods 0.000 description 13
230000005855 radiation Effects 0.000 description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
206010008089 Cerebral artery occlusion Diseases 0.000 description 12
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 12
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 12
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
125000005843 halogen group Chemical group 0.000 description 12
201000007309 middle cerebral artery infarction Diseases 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
230000000848 glutamatergic effect Effects 0.000 description 11
230000000324 neuroprotective effect Effects 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
206010027476 Metastases Diseases 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
230000007830 nerve conduction Effects 0.000 description 10
239000000126 substance Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
230000002491 angiogenic effect Effects 0.000 description 9
230000003542 behavioural effect Effects 0.000 description 9
230000001684 chronic effect Effects 0.000 description 9
238000003501 co-culture Methods 0.000 description 9
239000007788 liquid Substances 0.000 description 9
230000023105 myelination Effects 0.000 description 9
239000000047 product Substances 0.000 description 9
230000004044 response Effects 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
208000004454 Hyperalgesia Diseases 0.000 description 8
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 8
OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 8
239000002870 angiogenesis inducing agent Substances 0.000 description 8
125000004432 carbon atom Chemical group C* 0.000 description 8
238000002512 chemotherapy Methods 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
229940093499 ethyl acetate Drugs 0.000 description 8
238000007912 intraperitoneal administration Methods 0.000 description 8
230000009401 metastasis Effects 0.000 description 8
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
238000011160 research Methods 0.000 description 8
210000003497 sciatic nerve Anatomy 0.000 description 8
210000000273 spinal nerve root Anatomy 0.000 description 8
238000007920 subcutaneous administration Methods 0.000 description 8
229940124597 therapeutic agent Drugs 0.000 description 8
231100000331 toxic Toxicity 0.000 description 8
230000002588 toxic effect Effects 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
ACHMWJFCAQAIFA-UHFFFAOYSA-N 6-tritylsulfanylhexane-1,3,3-tricarboxylic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCCCC(CCC(=O)O)(C(O)=O)C(O)=O)C1=CC=CC=C1 ACHMWJFCAQAIFA-UHFFFAOYSA-N 0.000 description 7
208000024827 Alzheimer disease Diseases 0.000 description 7
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229940127089 cytotoxic agent Drugs 0.000 description 7
230000006870 function Effects 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
239000012044 organic layer Substances 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
208000020431 spinal cord injury Diseases 0.000 description 7
238000003756 stirring Methods 0.000 description 7
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
208000001613 Gambling Diseases 0.000 description 6
102000018899 Glutamate Receptors Human genes 0.000 description 6
108010027915 Glutamate Receptors Proteins 0.000 description 6
208000035154 Hyperesthesia Diseases 0.000 description 6
102000006386 Myelin Proteins Human genes 0.000 description 6
108010083674 Myelin Proteins Proteins 0.000 description 6
206010070834 Sensitisation Diseases 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
235000010323 ascorbic acid Nutrition 0.000 description 6
229960005070 ascorbic acid Drugs 0.000 description 6
239000011668 ascorbic acid Substances 0.000 description 6
238000003556 assay Methods 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
230000006399 behavior Effects 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
230000003492 excitotoxic effect Effects 0.000 description 6
210000005012 myelin Anatomy 0.000 description 6
229960002715 nicotine Drugs 0.000 description 6
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
230000037361 pathway Effects 0.000 description 6
239000002243 precursor Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
210000002307 prostate Anatomy 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000008313 sensitization Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
206010021143 Hypoxia Diseases 0.000 description 5
206010061216 Infarction Diseases 0.000 description 5
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
208000025966 Neurological disease Diseases 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
230000037396 body weight Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
210000002683 foot Anatomy 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 5
230000007574 infarction Effects 0.000 description 5
230000000302 ischemic effect Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
239000002858 neurotransmitter agent Substances 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
230000001242 postsynaptic effect Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000001953 sensory effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
125000000446 sulfanediyl group Chemical group *S* 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
208000000323 Tourette Syndrome Diseases 0.000 description 4
208000016620 Tourette disease Diseases 0.000 description 4
208000005298 acute pain Diseases 0.000 description 4
125000003302 alkenyloxy group Chemical group 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000002238 attenuated effect Effects 0.000 description 4
210000003050 axon Anatomy 0.000 description 4
239000002585 base Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
231100000318 excitotoxic Toxicity 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
210000000548 hind-foot Anatomy 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
230000002601 intratumoral effect Effects 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
230000006742 locomotor activity Effects 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
230000002981 neuropathic effect Effects 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 4
230000003518 presynaptic effect Effects 0.000 description 4
230000004224 protection Effects 0.000 description 4
208000020016 psychiatric disease Diseases 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
238000013222 sprague-dawley male rat Methods 0.000 description 4
238000011421 subcutaneous treatment Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
206010034158 Pathological gambling Diseases 0.000 description 3
208000018262 Peripheral vascular disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
229940025084 amphetamine Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
210000002469 basement membrane Anatomy 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
230000006957 competitive inhibition Effects 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
230000001804 emulsifying effect Effects 0.000 description 3
230000002461 excitatory amino acid Effects 0.000 description 3
239000003257 excitatory amino acid Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
230000000917 hyperalgesic effect Effects 0.000 description 3
230000001146 hypoxic effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
108010082117 matrigel Proteins 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
208000027232 peripheral nervous system disease Diseases 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
201000001514 prostate carcinoma Diseases 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
238000005096 rolling process Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
210000001044 sensory neuron Anatomy 0.000 description 3
230000020341 sensory perception of pain Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000946 synaptic effect Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
150000003573 thiols Chemical group 0.000 description 3
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
RWQDWWVQXIIQEU-UHFFFAOYSA-N 2,2-dimethyl-5-(3-tritylsulfanylpropyl)-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1CCCSC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 RWQDWWVQXIIQEU-UHFFFAOYSA-N 0.000 description 2
ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 description 2
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
DIMFHCPIUYUADX-UHFFFAOYSA-N 2-[[benzenesulfonamidomethyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CNS(=O)(=O)C1=CC=CC=C1 DIMFHCPIUYUADX-UHFFFAOYSA-N 0.000 description 2
SVAHMQCUSNJPRX-UHFFFAOYSA-N 2-[[hydroxy-[(2,3,4,5,6-pentafluorophenyl)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CC1=C(F)C(F)=C(F)C(F)=C1F SVAHMQCUSNJPRX-UHFFFAOYSA-N 0.000 description 2
TWDMUASLJTXKAN-UHFFFAOYSA-N 2-benzyl-3-sulfanylpentanoic acid Chemical compound CCC(S)C(C(O)=O)CC1=CC=CC=C1 TWDMUASLJTXKAN-UHFFFAOYSA-N 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
AECGEIVNZGQBJT-UHFFFAOYSA-N 3-tritylsulfanylpropanoic acid Chemical group C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCCC(=O)O)C1=CC=CC=C1 AECGEIVNZGQBJT-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
208000008035 Back Pain Diseases 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
206010012335 Dependence Diseases 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000004860 Dipeptidases Human genes 0.000 description 2
108090001081 Dipeptidases Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108010065372 Dynorphins Proteins 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
208000000461 Esophageal Neoplasms Diseases 0.000 description 2
208000006168 Ewing Sarcoma Diseases 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
229940123457 Free radical scavenger Drugs 0.000 description 2
210000000712 G cell Anatomy 0.000 description 2
208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
206010020710 Hyperphagia Diseases 0.000 description 2
206010021567 Impulsive behaviour Diseases 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
206010026673 Malignant Pleural Effusion Diseases 0.000 description 2
206010025538 Malignant ascites Diseases 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
102000003797 Neuropeptides Human genes 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
208000002471 Penile Neoplasms Diseases 0.000 description 2
206010034299 Penile cancer Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
206010042008 Stereotypy Diseases 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
208000004354 Vulvar Neoplasms Diseases 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
206010048010 Withdrawal syndrome Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
AQQVTZBWWYVEGR-UHFFFAOYSA-N [NH4+].[O-][PH2]=O Chemical compound [NH4+].[O-][PH2]=O AQQVTZBWWYVEGR-UHFFFAOYSA-N 0.000 description 2
238000002679 ablation Methods 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
230000006427 angiogenic response Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000007080 aromatic substitution reaction Methods 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
201000008247 brain infarction Diseases 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
231100000858 damage to nervous tissue Toxicity 0.000 description 2
230000034994 death Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
201000004101 esophageal cancer Diseases 0.000 description 2
FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical group CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 2
231100000063 excitotoxicity Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000003191 femoral vein Anatomy 0.000 description 2
230000035558 fertility Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
201000010175 gallbladder cancer Diseases 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
201000009277 hairy cell leukemia Diseases 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000010874 in vitro model Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
208000037819 metastatic cancer Diseases 0.000 description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical group COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000001022 morbid obesity Diseases 0.000 description 2
210000002161 motor neuron Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
210000000944 nerve tissue Anatomy 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000003961 neuronal insult Effects 0.000 description 2
230000004112 neuroprotection Effects 0.000 description 2
230000006959 non-competitive inhibition Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000002674 ointment Substances 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
235000020830 overeating Nutrition 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229910000343 potassium bisulfate Inorganic materials 0.000 description 2
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000003439 radiotherapeutic effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
210000004116 schwann cell Anatomy 0.000 description 2
230000035807 sensation Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
210000003594 spinal ganglia Anatomy 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
208000029387 trophoblastic neoplasm Diseases 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000006967 uncompetitive inhibition Effects 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
206010046885 vaginal cancer Diseases 0.000 description 2
208000013139 vaginal neoplasm Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000009736 wetting Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 1
OEWYWFJWBZNJJG-UHFFFAOYSA-N 1-(aziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CC1 OEWYWFJWBZNJJG-UHFFFAOYSA-N 0.000 description 1
PYWLBQPICCQJFF-XLPZGREQSA-N 1-[(2r,4s,5r)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CN)[C@@H](O)C1 PYWLBQPICCQJFF-XLPZGREQSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
CARFETJZUQORNQ-UHFFFAOYSA-N 1h-pyrrole-2-thiol Chemical class SC1=CC=CN1 CARFETJZUQORNQ-UHFFFAOYSA-N 0.000 description 1
XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
USTZJUOEIVGBAX-UHFFFAOYSA-N 2-(2-benzyl-3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(CS)CC1=CC=CC=C1 USTZJUOEIVGBAX-UHFFFAOYSA-N 0.000 description 1
MCFINHFDKVMWEK-UHFFFAOYSA-N 2-(2-methyl-3-sulfanylpropyl)pentanedioic acid Chemical compound SCC(CC(C(=O)O)CCC(=O)O)C.SCC(CC(C(=O)O)CCC(=O)O)C MCFINHFDKVMWEK-UHFFFAOYSA-N 0.000 description 1
BGFCWVUFLJLKGR-UHFFFAOYSA-N 2-(2-phenyl-3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(CS)C1=CC=CC=C1 BGFCWVUFLJLKGR-UHFFFAOYSA-N 0.000 description 1
YXDFSJDPIASAJM-UHFFFAOYSA-N 2-(2-sulfanyl-2-sulfanylideneethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CC(S)=S YXDFSJDPIASAJM-UHFFFAOYSA-N 0.000 description 1
QFKHEJQVTSTWPJ-UHFFFAOYSA-N 2-(4-sulfanylbutyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCCCS QFKHEJQVTSTWPJ-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
STVOADPTYLILCQ-UHFFFAOYSA-N 2-(pyridin-3-ylmethyl)-4-sulfanylpentanoic acid Chemical compound CC(S)CC(C(O)=O)CC1=CC=CN=C1 STVOADPTYLILCQ-UHFFFAOYSA-N 0.000 description 1
MWBHTIUXURSWKA-UHFFFAOYSA-N 2-(pyridin-4-ylmethyl)-3-sulfanylpentanoic acid Chemical compound CCC(S)C(C(O)=O)CC1=CC=NC=C1 MWBHTIUXURSWKA-UHFFFAOYSA-N 0.000 description 1
LGBHWCHYODMSKL-UHFFFAOYSA-N 2-[[(2-fluorophenyl)methyl-hydroxyphosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CC1=CC=CC=C1F LGBHWCHYODMSKL-UHFFFAOYSA-N 0.000 description 1
LKDUVRIWOPSOJJ-UHFFFAOYSA-N 2-[[(4-fluoroanilino)methyl-hydroxyphosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CNC1=CC=C(F)C=C1 LKDUVRIWOPSOJJ-UHFFFAOYSA-N 0.000 description 1
IXFRJFZORBETIP-UHFFFAOYSA-N 2-[[(benzylamino)methyl-hydroxyphosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CNCC1=CC=CC=C1 IXFRJFZORBETIP-UHFFFAOYSA-N 0.000 description 1
GZNKYXXCKRYSFH-UHFFFAOYSA-N 2-[[2-carboxyethyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CCC(O)=O GZNKYXXCKRYSFH-UHFFFAOYSA-N 0.000 description 1
YORKEEVUCGQRPP-UHFFFAOYSA-N 2-[[2-carboxypentyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound CCCC(C(O)=O)CP(O)(=O)CC(C(O)=O)CCC(O)=O YORKEEVUCGQRPP-UHFFFAOYSA-N 0.000 description 1
FFXVQVAPAACMHP-UHFFFAOYSA-N 2-[[2-carboxypropyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)C(C)CP(O)(=O)CC(C(O)=O)CCC(O)=O FFXVQVAPAACMHP-UHFFFAOYSA-N 0.000 description 1
HQMGMUAUNMHNSQ-UHFFFAOYSA-N 2-[[[(benzylamino)-phenylmethyl]-hydroxyphosphoryl]methyl]pentanedioic acid Chemical compound C=1C=CC=CC=1C(P(O)(=O)CC(CCC(=O)O)C(O)=O)NCC1=CC=CC=C1 HQMGMUAUNMHNSQ-UHFFFAOYSA-N 0.000 description 1
JXSWTJRRHINJFL-UHFFFAOYSA-N 2-[[[(carboxyamino)-phenylmethyl]-hydroxyphosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)C(NC(O)=O)C1=CC=CC=C1 JXSWTJRRHINJFL-UHFFFAOYSA-N 0.000 description 1
ZCFZUOJYCNXDCI-UHFFFAOYSA-N 2-[[acetamidomethyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound CC(=O)NCP(O)(=O)CC(C(O)=O)CCC(O)=O ZCFZUOJYCNXDCI-UHFFFAOYSA-N 0.000 description 1
RGKXFQRASRKMLR-UHFFFAOYSA-N 2-[[anilinomethyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CNC1=CC=CC=C1 RGKXFQRASRKMLR-UHFFFAOYSA-N 0.000 description 1
MIINQJNPWDYQGB-UHFFFAOYSA-N 2-[[butyl(hydroxy)phosphoryl]methyl]pentanedioic acid Chemical compound CCCCP(O)(=O)CC(C(O)=O)CCC(O)=O MIINQJNPWDYQGB-UHFFFAOYSA-N 0.000 description 1
VAZDQVAVNHZARH-UHFFFAOYSA-N 2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)CCCC1=CC=CC=C1 VAZDQVAVNHZARH-UHFFFAOYSA-N 0.000 description 1
CAGAVCIHAJPIJR-UHFFFAOYSA-N 2-[[hydroxy(methyl)phosphoryl]methyl]pentanedioic acid Chemical compound CP(O)(=O)CC(C(O)=O)CCC(O)=O CAGAVCIHAJPIJR-UHFFFAOYSA-N 0.000 description 1
UIVPEQQNMNDWDC-UHFFFAOYSA-N 2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)C1=CC=CC=C1 UIVPEQQNMNDWDC-UHFFFAOYSA-N 0.000 description 1
KWUQXTWAEHRRNT-UHFFFAOYSA-N 2-[[hydroxy-[(3-methylphenyl)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound CC1=CC=CC(CP(O)(=O)CC(CCC(O)=O)C(O)=O)=C1 KWUQXTWAEHRRNT-UHFFFAOYSA-N 0.000 description 1
UGQHMJXTPJHMFZ-UHFFFAOYSA-N 2-[[hydroxy-[(4-methoxyanilino)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound COC1=CC=C(NCP(O)(=O)CC(CCC(O)=O)C(O)=O)C=C1 UGQHMJXTPJHMFZ-UHFFFAOYSA-N 0.000 description 1
CHTREKLBQHLOFC-UHFFFAOYSA-N 2-[[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound COC1=CC=C(CP(O)(=O)CC(CCC(O)=O)C(O)=O)C=C1 CHTREKLBQHLOFC-UHFFFAOYSA-N 0.000 description 1
SGHXIBIWMTUHFJ-UHFFFAOYSA-N 2-[[hydroxy-[(4-methylanilino)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound CC1=CC=C(NCP(O)(=O)CC(CCC(O)=O)C(O)=O)C=C1 SGHXIBIWMTUHFJ-UHFFFAOYSA-N 0.000 description 1
PNLBDTBPSPYQJD-UHFFFAOYSA-N 2-[[hydroxy-[(n-phenylanilino)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound C=1C=CC=CC=1N(CP(O)(=O)CC(CCC(=O)O)C(O)=O)C1=CC=CC=C1 PNLBDTBPSPYQJD-UHFFFAOYSA-N 0.000 description 1
WBIDFRDQHBMYJE-UHFFFAOYSA-N 2-[[hydroxy-[hydroxy(phenyl)methyl]phosphoryl]methyl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(=O)C(O)C1=CC=CC=C1 WBIDFRDQHBMYJE-UHFFFAOYSA-N 0.000 description 1
ZUEBVBPVXLQMQR-UHFFFAOYSA-N 2-benzyl-3-sulfanylpropanoic acid Chemical compound OC(=O)C(CS)CC1=CC=CC=C1 ZUEBVBPVXLQMQR-UHFFFAOYSA-N 0.000 description 1
WKAKGVJRWRLYHS-UHFFFAOYSA-N 2-benzyl-4-sulfanylbutanoic acid Chemical compound SCCC(C(=O)O)CC1=CC=CC=C1 WKAKGVJRWRLYHS-UHFFFAOYSA-N 0.000 description 1
HDNAGGDPUMXKDI-UHFFFAOYSA-N 2-benzyl-4-sulfanylpentanoic acid Chemical compound CC(S)CC(C(O)=O)CC1=CC=CC=C1 HDNAGGDPUMXKDI-UHFFFAOYSA-N 0.000 description 1
XPBJPGMCFKYBBV-UHFFFAOYSA-N 2-bromoethyl-[2-hydroxy-3-(2-nitroimidazol-1-yl)propyl]azanium;bromide Chemical compound Br.BrCCNCC(O)CN1C=CN=C1[N+]([O-])=O XPBJPGMCFKYBBV-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
150000004959 2-nitroimidazoles Chemical class 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
ADWMKGCKKNULPN-UHFFFAOYSA-N 2-sulfinylpyrrole Chemical class O=S=C1C=CC=N1 ADWMKGCKKNULPN-UHFFFAOYSA-N 0.000 description 1
JRZBWRPPYOMOJE-UHFFFAOYSA-N 2-sulfonylpyrrole Chemical class O=S(=O)=C1C=CC=N1 JRZBWRPPYOMOJE-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
NUGLIYXAARVRPQ-UHFFFAOYSA-N 3-(2-nitroimidazol-1-yl)propane-1,2-diol Chemical compound OCC(O)CN1C=CN=C1[N+]([O-])=O NUGLIYXAARVRPQ-UHFFFAOYSA-N 0.000 description 1
IVYRPDPNOXSIGO-UHFFFAOYSA-N 3-(2-sulfanylethyl)pentane-1,3,5-tricarboxylic acid Chemical compound OC(=O)CCC(CCS)(C(O)=O)CCC(O)=O IVYRPDPNOXSIGO-UHFFFAOYSA-N 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
WRSDJJXJDSEUSQ-UHFFFAOYSA-N 5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)CCCC(=O)OCC1=CC=CC=C1 WRSDJJXJDSEUSQ-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000238876 Acari Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
101001044245 Arabidopsis thaliana Insulin-degrading enzyme-like 1, peroxisomal Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
108010070075 Bacteriochlorophyll A Proteins 0.000 description 1
208000006373 Bell palsy Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
YLVWAPXLWBWJIX-UHFFFAOYSA-N C(C=C)(=O)OCC1=CC=CC=C1.C=C(C(=O)OCC1=CC=CC=C1)CCC(=O)OCC1=CC=CC=C1 Chemical compound C(C=C)(=O)OCC1=CC=CC=C1.C=C(C(=O)OCC1=CC=CC=C1)CCC(=O)OCC1=CC=CC=C1 YLVWAPXLWBWJIX-UHFFFAOYSA-N 0.000 description 1
KDHUHPMQUROTOM-UHFFFAOYSA-N C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O Chemical compound C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O KDHUHPMQUROTOM-UHFFFAOYSA-N 0.000 description 1
MPAWFRNWRJOTLF-UHFFFAOYSA-N C1=CC=C(C(=C1)F)P(=O)(CC(CCC(=O)O)C(=O)O)O Chemical compound C1=CC=C(C(=C1)F)P(=O)(CC(CCC(=O)O)C(=O)O)O MPAWFRNWRJOTLF-UHFFFAOYSA-N 0.000 description 1
229910014585 C2-Ce Inorganic materials 0.000 description 1
BATVLUUHUPBPJN-UHFFFAOYSA-N CC(C)(C)OC(=O)CCC(C(=O)OC(C)(C)C)CP(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)CCC(C(=O)OC(C)(C)C)CP(=O)OC(C)(C)C BATVLUUHUPBPJN-UHFFFAOYSA-N 0.000 description 1
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282465 Canis Species 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010051290 Central nervous system lesion Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
230000008265 DNA repair mechanism Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
206010012225 Delirium tremens Diseases 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
KMSNYNIWEORQDJ-UHFFFAOYSA-N Dihydro-2(3H)-thiophenone Chemical compound O=C1CCCS1 KMSNYNIWEORQDJ-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
206010013486 Distractibility Diseases 0.000 description 1
206010013647 Drowning Diseases 0.000 description 1
206010013752 Drug withdrawal convulsions Diseases 0.000 description 1
102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
108010074604 Epoetin Alfa Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
206010016845 Foetal alcohol syndrome Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
229940127337 Glycine Antagonists Drugs 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
208000003698 Heroin Dependence Diseases 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000015592 Involuntary movements Diseases 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
208000006264 Korsakoff syndrome Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
241000883511 Lophophora williamsii Species 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
238000006845 Michael addition reaction Methods 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
108010090363 N-acetylaspartyl-beta-linked glutamate Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
206010029301 Neurological disorders of the eye Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000000114 Pain Threshold Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000097929 Porphyria Species 0.000 description 1
208000010642 Porphyrias Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102100024622 Proenkephalin-B Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
230000002292 Radical scavenging effect Effects 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
240000002825 Solanum vestissimum Species 0.000 description 1
235000018259 Solanum vestissimum Nutrition 0.000 description 1
206010041591 Spinal osteoarthritis Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
102100033055 Transketolase Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
208000036826 VIIth nerve paralysis Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
231100000569 acute exposure Toxicity 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
210000002551 anterior cerebral artery Anatomy 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
210000001142 back Anatomy 0.000 description 1
DSJXIQQMORJERS-DHHJBRQQSA-O bacteriochlorophyll a Chemical compound [Mg+2].[N-]1C(C=C2[C@H]([C@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=[NH+]2)C2=C3[N-]C(=C4)C(C)=C3C(=O)[C@H]2C(=O)OC)C)=C(C)C(C(C)=O)=C1C=C1[C@@H](C)[C@H](CC)C4=[NH+]1 DSJXIQQMORJERS-DHHJBRQQSA-O 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
AOJOEFVRHOZDFN-UHFFFAOYSA-N benzyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC1=CC=CC=C1 AOJOEFVRHOZDFN-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
230000004397 blinking Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000002318 cardia Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229940111221 carmustine 100 mg Drugs 0.000 description 1
210000000269 carotid artery external Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
206010007776 catatonia Diseases 0.000 description 1
230000000453 cell autonomous effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003874 central nervous system depressant Substances 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
208000036319 cervical spondylosis Diseases 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000009693 chronic damage Effects 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
230000009194 climbing Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229960000860 dapsone Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
KWHDKWRAUSRBKK-UHFFFAOYSA-N dibenzyl 2-[bis(phenylmethoxy)phosphorylmethyl]pentanedioate dibenzyl hydrogen phosphite Chemical compound P(OCC1=CC=CC=C1)(OCC1=CC=CC=C1)O.C(C1=CC=CC=C1)OP(=O)(OCC1=CC=CC=C1)CC(C(=O)OCC1=CC=CC=C1)CCC(=O)OCC1=CC=CC=C1 KWHDKWRAUSRBKK-UHFFFAOYSA-N 0.000 description 1
ACXSUJZCYZEUIF-UHFFFAOYSA-N dibenzyl 2-methylidenepentanedioate Chemical compound C=1C=CC=CC=1COC(=O)C(=C)CCC(=O)OCC1=CC=CC=C1 ACXSUJZCYZEUIF-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009429 distress Effects 0.000 description 1
125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
VQBPMUQSMPMKGW-UHFFFAOYSA-N ditert-butyl 2-methylidenepentanedioate Chemical compound CC(C)(C)OC(=O)CCC(=C)C(=O)OC(C)(C)C VQBPMUQSMPMKGW-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000074 effect on parkinson Effects 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229960003388 epoetin alfa Drugs 0.000 description 1
WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
229950006566 etanidazole Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
QPBGUMQHELYSIP-UHFFFAOYSA-N ethyl 3-(2-oxothiolan-3-yl)propanoate Chemical compound CCOC(=O)CCC1CCSC1=O QPBGUMQHELYSIP-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
229940009626 etidronate Drugs 0.000 description 1
229940065639 etoposide 100 mg Drugs 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
201000007794 fetal alcohol syndrome Diseases 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229940110363 floxuridine 500 mg Drugs 0.000 description 1
229940116447 fludarabine phosphate 50 mg Drugs 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000005153 frontal cortex Anatomy 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
229960002972 glutethimide Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940002989 goserelin 3.6 mg Drugs 0.000 description 1
229960003607 granisetron hydrochloride Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000001344 hyperglutamatergic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000012760 immunocytochemical staining Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000016245 inborn errors of metabolism Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
208000015978 inherited metabolic disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
108010076560 isospaglumic acid Proteins 0.000 description 1
150000003854 isothiazoles Chemical class 0.000 description 1
150000002545 isoxazoles Chemical class 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006996 mental state Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
229960001252 methamphetamine Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960002803 methaqualone Drugs 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
229960000316 methyprylon Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
229950010514 misonidazole Drugs 0.000 description 1
230000004065 mitochondrial dysfunction Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001343 mnemonic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000002969 morbid Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
229960004918 nimorazole Drugs 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000011474 orchiectomy Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000013348 organic food Nutrition 0.000 description 1
239000011368 organic material Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
229960004535 oxazepam Drugs 0.000 description 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000037040 pain threshold Effects 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
XDEPVFFKOVDUNO-UHFFFAOYSA-N pentafluorobenzyl bromide Chemical compound FC1=C(F)C(F)=C(CBr)C(F)=C1F XDEPVFFKOVDUNO-UHFFFAOYSA-N 0.000 description 1
JFCQEDHGNNZCLN-MABBKULESA-N pentanedioic acid Chemical class O[14C](=O)CCC[14C](O)=O JFCQEDHGNNZCLN-MABBKULESA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
125000005541 phosphonamide group Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
229940109328 photofrin Drugs 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229950010456 pimonidazole Drugs 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
230000002360 prefrontal effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
201000008752 progressive muscular atrophy Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
210000004908 prostatic fluid Anatomy 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
230000002385 psychotomimetic effect Effects 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000002534 radiation-sensitizing agent Substances 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
229940100618 rectal suppository Drugs 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
GUCKKCMJTSNWCU-BQBZGAKWSA-N spaglumic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(=O)N[C@H](C(O)=O)CCC(O)=O GUCKKCMJTSNWCU-BQBZGAKWSA-N 0.000 description 1
229960000341 spaglumic acid Drugs 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
208000005801 spondylosis Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
229940006509 strontium-89 Drugs 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
210000002504 synaptic vesicle Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
SWFSRMBSDMJGOK-UHFFFAOYSA-N thiadiazol-4-ol Chemical class OC1=CSN=N1 SWFSRMBSDMJGOK-UHFFFAOYSA-N 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000002972 tibial nerve Anatomy 0.000 description 1
208000016686 tic disease Diseases 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
125000005455 trithianyl group Chemical group 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL140499A 1998-07-06 2000-12-22 Nalladase inhibitors useful as pharmaceutical compounds and compositions IL140499A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US11018698A	1998-07-06	1998-07-06
US09/110,262 US6395718B1 (en)	1998-07-06	1998-07-06	Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US09/228,391 US6265609B1 (en)	1998-07-06	1999-01-12	Thio-substituted pentanedioic acid derivatives
PCT/US1999/015128 WO2000001668A2 (fr)	1998-07-06	1999-07-02	INHIBITEURS DE NAALADase UTILES COMME COMPOSES ET COMPOSITIONS PHARMACEUTIQUES

Publications (1)

Publication Number	Publication Date
IL140499A true IL140499A (en)	2006-12-31

Family

ID=40639568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL140499A IL140499A (en)	1998-07-06	2000-12-22	Nalladase inhibitors useful as pharmaceutical compounds and compositions

Country Status (3)

Country	Link
JP (1)	JP2010001312A (fr)
CA (1)	CA2658200A1 (fr)
IL (1)	IL140499A (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5142175B2 (fr) *	1973-07-04	1976-11-13
JPS57116045A (en) *	1981-01-13	1982-07-19	Tokyo Organ Chem Ind Ltd	Dithiocarbamate, its preparation and injurious organism exterminatory agent consisting of said dithiocarbamate
JPS5810565A (ja) *	1981-07-09	1983-01-21	Tanabe Seiyaku Co Ltd	トリプトフアン誘導体及びその製法
JPS5810558A (ja) *	1981-07-09	1983-01-21	Tanabe Seiyaku Co Ltd	新規アミノ酸誘導体及びその製法
JPS6153285A (ja) *	1984-08-24	1986-03-17	Kyowa Hakko Kogyo Co Ltd	β−ラクタム化合物
JPH01206338A (ja) *	1988-02-15	1989-08-18	Konica Corp	ハロゲン化銀カラー写真感光材料
US5807884A (en) *	1992-10-30	1998-09-15	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
CN1057907C (zh) *	1995-06-13	2000-11-01	北京医科大学	驱镉药物及其合成方法和应用
ID18382A (id) *	1996-09-27	1998-04-02	Guilford Pharm Inc	Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase

1999
- 1999-07-02 CA CA002658200A patent/CA2658200A1/fr not_active Abandoned
2000
- 2000-12-22 IL IL140499A patent/IL140499A/en not_active IP Right Cessation
2009
- 2009-09-30 JP JP2009228198A patent/JP2010001312A/ja active Pending

Also Published As

Publication number	Publication date
JP2010001312A (ja)	2010-01-07
CA2658200A1 (fr)	2000-01-13

Legal Events

Date	Code	Title	Description
2014-02-27	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
RU2268881C2 (ru)	2006-01-27	Производные пентадикарбоновой кислоты, фармацевтическая композиция на их основе и способы лечения
US6458775B1 (en)	2002-10-01	NAALADase inhibitors useful as pharmaceutical compounds and compositions
US6313159B1 (en)	2001-11-06	Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
AU733880B2 (en)	2001-05-31	Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US6265609B1 (en)	2001-07-24	Thio-substituted pentanedioic acid derivatives
US6452044B2 (en)	2002-09-17	Benzenedicarboxylic acid derivatives
JP2001527084A (ja)	2001-12-25	Ｎａａｌｄアーゼ阻害剤のプロドラッグ
US6071965A (en)	2000-06-06	Phosphinic alkanoic acid derivatives
JP2001521512A (ja)	2001-11-06	Ｎａａｌａｄａｓｅインヒビターとしてのチオ誘導体類
WO2003057670A2 (fr)	2003-07-17	Indoles en tant qu'inhibiteurs de l'enzyme naaladase
US6121252A (en)	2000-09-19	Phosphinic acid derivatives
WO2001034596A2 (fr)	2001-05-17	DERIVES DE PYRROLECARBONYLIMINO UTILISES COMME INHIBITEURS DE LA NAALADase
IL140499A (en)	2006-12-31	Nalladase inhibitors useful as pharmaceutical compounds and compositions
HK1083017A (en)	2006-06-23	Naaladase inhibitors useful as pharmaceutical compounds and compositions
HK1036617B (en)	2006-02-03	Naaladase inhibitors useful as pharmaceutical compounds and compositions
MXPA00006283A (en)	2001-12-13	Prodrugs of naaladase inhibitors